SignalCorporate
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
Biogen Q3 preview questions whether growth products will drive an earnings beat.
Context
What happened: Zacks expects Biogen $BIIB to beat expectations when it reports third-quarter 2026 results on Oct. 28, before market open, citing growth products offsetting lower multiple sclerosis drug sales.
Key numbers: Consensus Q3 sales $2.60 billion and earnings $2.05 per share.
Why it matters: The model predicts an earnings beat on the combination of a positive Earnings ESP and Zacks Rank #3. Growth products exceeded legacy MS portfolio revenue in the second quarter and are expected to keep the lead in the second half of 2026.
Market: -0.1% today ($250.31), +40.8% YTD, 0.1x vol — as of 15:32 UTC
Verified: Q3_2026 (Oct 28) revenue $2.6B vs $2.6B est; next print ~Jan 27
What changed
Zacks expects Biogen $BIIB to beat expectations when it reports third-quarter 2026 results on Oct. 28, before market open, citing growth products offsetting lower multiple sclerosis drug sales.
Why it matters
The model predicts an earnings beat on the combination of a positive Earnings ESP and Zacks Rank #3. Growth products exceeded legacy MS portfolio revenue in the second quarter and are expected to keep the lead in the second half of 2026.
Market: -0.1% today ($250.31), +40.8% YTD, 0.1x vol — as of 15:32 UTC
Verified: Q3_2026 (Oct 28) revenue $2.6B vs $2.6B est; next print ~Jan 27